HIT Consultant December 7, 2023
Syed Hamza Sohail

What You Should Know:

  • Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that the company has initiated the first-in-human study for ISM5411, a potentially first-in-class PHD inhibitor for the treatment of inflammatory bowel disease (IBD).
  • Designed and developed by Insilico’s proprietary end-to-end AI drug discovery platform, Pharma.AI, ISM5411 is Insilico’s fifth AI drug program to enter the clinic.

AI-Driven Advancements in the Eradication of GI Diseases

Insilico’s Phase I study of ISM5411, aimed at assessing safety, tolerability, pharmacokinetics, and food effects in 76 healthy subjects, has completed its initial dose in Australian volunteers. Following Phase Ia, the company plans global Phase Ib trials for ulcerative colitis patients. Inflammatory bowel disease (IBD), including...

Today's Sponsors


Today's Sponsor


Topics: AI (Artificial Intelligence), Biotechnology, Pharma / Biotech, Technology
Artificial Intelligence in Healthcare: New Avenues for Liability
Anthropic gives its flagship generative AI models a facelift
Why OpenAI’s nonprofit mission to build AGI is under fire — again | The AI Beat
Intelligent Scopes launches GI platform
OpenAI challenger Anthropic launches Claude 3 chatbot suite

Share This Article